Health insurer Premera Blue Cross has backed a $6.1m series A round for Cardinal Analytx, developer of technology that calculates the potential risk of new policy buyers.

Evotec has invested $17.7m in Exscientia, becoming the first strategic shareholder in the drug discovery spinout, which is based on research at University of Dundee.

Alexandria Real Estate Equities has contributed to a $76m round for KSQ, which is developing genomics-focused oncology and immunology drugs.

AbbVie Ventures has participated in a $20m round that will support nanotechnology drug developer Exicure's reverse merger with a shell company.

Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.